APOP Stock Shares Surge On Positive Stem Cell Trial
Warrior Trading | Jan 05, 2018 12:41AM ET
Cellect Biotechnology Ltd (NASDAQ:APOP)
On Thursday before the market opened shares of Cellect Biotechnology ($APOP) skyrocketed over 50% after they announced a successful stem cell trial.
The company had successfully made a transplant using their proprietary ApoGraft technology in a phase II trial with 3 patients. This is a huge step in this field of research and could be the first major breakthrough in stem cell transplantation.
h3 APOP Technicals/h3Shares are up 72% at of the time of this writing with a current premarket bid of $12.25 after closing Wednesday at $7.12. Shares of $APOP will be very active today with increased volatility .
Look for resistance to come in at $13.50 and then whole and half dollar numbers after that. Support will be met at $10.50, $10 and $9.50. Shares have been stuck between $10 and $6 for a long time now so this breakout will be definitely spark some interest with traders.
There will be plenty of opportunity on this name today so make sure to keep it on your radar!
h3 CEO Comments/h3Dr. Shai Yarkoni, Cellect’s CEO said :
h3 Company Profile/h3“Our ApoGraft™ technology shows consistently successful results in the use of stem cell transplants for treating patients suffering from life-threatening conditions. We see our position strengthened with each patient treated. We aim for stem cell based regenerative medicine to become a safe and affordable treatment for most of mankind’s diseases.”
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection.
The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.